FindMyKOL
Clinical trialNCT06001762Active, not recruitingPhase 2Interventional

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

SponsorDana-Farber Cancer InstituteEnrollment90Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage high-risk hormone receptor positive breast cancer. The names of the study drugs involved in this study are: * Abemaciclib (CDK4 and CDK6 inhibitor) * Tamoxifen (Selective estrogen receptor modulator) * Anastrozole/Letrozole (Non-steroidal aromatase inhibitors) * Exemestane (steroidal aromatase inhibitor) * LHRH (Gonadotropin-releasing hormone agonist, or Luteinizing hormone-releasing hormone agonist)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stamford Hospital

    Stamford, Connecticut, United States

  • Eastern Maine Medical Center (northern Light)

    Brewer, Maine, United States

  • New England Cancer Specialists

    Scarborough, Maine, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Boston Medical Center

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute at Steward St. Elizabeth'S

    Brighton, Massachusetts, United States

  • Dana-Farber Cancer Institute at Foxborough

    Foxborough, Massachusetts, United States

  • Dana-Farber Cancer Institute at Merrimack Valley

    Methuen, Massachusetts, United States

  • Dana-Farber Cancer Institute at Milford

    Milford, Massachusetts, United States

  • Dana-Farber Cancer Institute at South Shore

    South Weymouth, Massachusetts, United States

  • Dana-Farber Cancer Insitute at Londonderry Hospital

    Londonderry, New Hampshire, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abemaciclib →Anastrozole →Exemestane →LHRH agonist →Letrozole →Tamoxifen →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Oct 2023
Primary completion
22 Jan 2025
Completion
1 Jan 2027
Last update posted
2 Jul 2026
Registered enrollment
90
Registry id
NCT06001762
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.